Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05787834

Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Cancer

This clinical trial evaluates whether home-based respiratory muscle training is useful for minimizing side effects in patients undergoing treatment for cancer. Over-activation of the nervous system during breast cancer treatment can result in heart- and lung-related side effects which have the potential to reduce a patient's quality of life. Aerobic exercise can help prevent the development of these side effects. However, engaging in regular aerobic exercise may be difficult for breast cancer patients who are actively undergoing treatment. Respiratory muscle training (RMT) involves a series of breathing and other exercises that are performed to improve the function of the respiratory muscles through resistance and endurance training. Home-based RMT may represent a more feasible approach for reducing side effects in patients undergoing treatment for breast cancer.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Roswell Park Cancer Institute

Buffalo, New York, 14263, United States

Location status: Recruiting

Location contact

Ellis Levine, MD

CONTACT

[email protected]

716-845-3152

Ellis Levine, MD

PRINCIPAL_INVESTIGATOR

About this study

PRIMARY OBJECTIVE:

I. To assess the feasibility of delivering a 12-week RMT program during adjuvant and neoadjuvant chemotherapy used to treat breast cancer, head and neck cancer and lung cancer.

SECONDARY OBJECTIVES:

I. To determine how cardiac autonomic regulation, cardiorespiratory fitness, exercise performance, and quality-of-life (QoL) are affected by RMT during breast cancer treatment.

II. To assess how RMT affects patient reported symptoms linked to sympathetic overactivation such as stress, fatigue, dyspnea, when performed during chemotherapy.

EXPLORATORY OBJECTIVE:

I. To determine if RMT reduces circulating biomarkers of autonomic dysfunction, inflammation, and cardiac injury in breast cancer patients undergoing treatment.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: patients receive lower resistance RMT using a respiratory muscle training device for 12 weeks.

GROUP II: Patients undergo higher resistance RMT using a respiratory muscle training device for 12 weeks on study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Documented breast cancer and scheduled to receive adjuvant or neoadjuvant chemotherapy
  • Age >= 21 years old
  • Diagnosed with solid tumor (e.g., head and neck, thoracic, or breast cancer)
  • Scheduled to receive at least one dose of chemotherapy or immunotherapy or radiation
  • Treated at Roswell Park Comprehensive Cancer Center

Exclusion criteria

  • Presence of oral mucosal disease including oral mucositis, or oral candidiasis detected at baseline
  • Have uncontrolled intercurrent illness including, but not limited to, ongoing or active respiratory infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, heart failure or psychiatric illness/social situations that would limit compliance with study requirements
  • Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study intervention

Treatment and study plan

Best Practice

Other

Receive usual care

Other names: standard of care, standard therapy

Medical Device Usage and Evaluation

Other

Wear accelerometer

Respiratory Muscle Training

Procedure

Undergo RMT

Other names: RMT

Survey Administration

Other

Ancillary studies

Primary outcomes

  1. Proportion of patients who participate in the study

    Time frame: Up to 12 weeks

  2. Proportion of patients who remain on study

    Time frame: Up to 12 weeks

  3. Proportion of patients who perform >= 3 respiratory muscle training (RMT) sessions/week

    Time frame: Up to 12 weeks

    Overall compliance rates (compliance at all time points) will be estimated using 90% confidence intervals. Additionally, compliance status will be modeled as a function of time (e.g., week), and pre-specified exogenous factors (e.g., baseline age, performance status, self-reported history of exercise, breast cancer (BC) treatment received, treatment side-effects) using a generalized estimating equation (GEE) logistic regression model (auto-regressive covariance structure). Estimates of compliance rates will be obtained by time-point and tests about the appropriate contrasts of model estimates will be used to determine if there is a time trend.

  4. Proportion of patients who perform > 70% of their RMT sessions

    Time frame: Up to 12 weeks

    Adherence rates (completion of >= 70% of sessions) will be estimated using 90% confidence intervals. Additionally, compliance status will be modeled as a function of time (e.g., week), and pre-specified exogenous factors (e.g., baseline age, performance status, self-reported history of exercise, BC treatment received, treatment side-effects) using a GEE logistic regression model (auto-regressive covariance structure). Estimates of compliance rates will be obtained by time-point and tests about the appropriate contrasts of model estimates will be used to determine if there is a time trend.

Secondary outcomes

  1. Change in Functional Capacity

    Time frame: At baseline, 6 weeks, and 12 weeks

    Six minute walking test is a functional test of sub-maximum cardiorespiratory capacity.

  2. Change in Lower body strength

    Time frame: At baseline, 6 weeks, and 12 weeks

    The Short Physical Performance Battery - PPB is comprised of 3 tasks: a hierarchial standing balance test (side by side, semi-tandem and tandem), 4-m habitual gait speed, and 5 sit to stand from a chair. Each task is scored (based on time) from 0-4 Points (p) and then summarized into a total score of 0-12 p, where 12 p represents the highest performance.

  3. Assess Dyspnea

    Time frame: At baseline, 6 weeks, and 12 weeks

    Dyspnea will be measured by the Dyspnea-12 questionnaire which contains 12 items on a scale of 0(none), mild (1) and Severe (3) and evaluates the physical and affective dimensions of dyspnea. Higher scores represent greater severity.

  4. Assess Fatigue

    Time frame: At baseline, 6 weeks, and 12 weeks

    Fatigue will be measured using the Brief Fatigue Inventory (BFI). Each item is scored 1 (no fatigue) to 10 (as bad as you can imagine) to assess the severity of fatigue and its impact on daily functioning. A global fatigue score is obtained by averaging all the items (1-3: mild, 4-7: moderate, 8-10: severe)

  5. Change in Quality of life

    Time frame: At baseline, 6 weeks, and 12 weeks

    Quality of life collected by the EORTC Core Quality of Life Questionnaire (EORTC-QLQ-30) - a 30 question questionnaire with lower higher scores indicating a positive situation.

  6. Sleep quality

    Time frame: At baseline, 6 weeks, and 12 weeks

    Will be measured by the Pittsburg Sleep Quality Index a self reported inventory to measure sleep quality. Questions are answered on 0-3 scale with higher scores indicating greater sleep pathology.

  7. Anxiety

    Time frame: At baseline, 6 weeks, and 12 weeks

    The Beck Anxiety Score is a measurement on a scale from 0 to 63 obtained by using the Beck Anxiety Inventory tool to assess symptoms of anxiety. A higher score correlates to increased anxiety whereas a lower score expresses a lower amount of anxiety.

  8. Self-reported measures of stress

    Time frame: At baseline, 6 weeks, and 12 weeks

    Stress will be measured by the Perceived Stress Scale. The scale measures the degree to which one perceives situations in one's life as stressful on a Likert Scale of 0 to 4 with 0 indicating never, and 4 indicating very often. Higher scores indicate higher levels of perceived stress

  9. Self-reported measures of depression

    Time frame: At baseline, 6 weeks, and 12 weeks

    Will be measured by the Centers for Epidemiology Studies Depression Scale used as a screen to identify clinically significant depression; a cutoff score of greater than 16 has been shown to correlate with clinically significant depression. In addition, a score between 8 and 15 has been used to define subsyndromal depression. The possible range of scores is zero to 60, with the higher scores indicating more symptoms, weighted by frequency of occurrence during the past week.

  10. Measures of fitness

    Time frame: At baseline, 6 weeks, and 12 weeks

    Will be measured with a submaximal exercise test. A 6 minute cycling exercise test.

Study contacts

Contact information is provided by the study sponsor or research team.

Sponsors and collaborators

Lead sponsor

Roswell Park Cancer Institute

Other

Registry information

Official study title

Respiratory Muscle Training During Cancer Treatment: Effects on the Autonomic Nervous System and Cardiotoxicity

Important dates

Study start
2023
Primary completion
2028
Study completion
2029
First posted
Mar 28, 2023
Registry last updated
May 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.